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Abstract  23 
With the dramatic consequences of bacterial resistance to antibiotics, nanomaterials and 24 
molecular transporters have started to be investigated as alternative antibacterials or anti-25 
  
infective carrier systems to improve the internalization of bactericidal drugs. However, the 26 
capability of nanomaterials/molecular transporters to overcome the bacterial cell envelope is 27 
poorly understood. It is critical to consider the sophisticated architecture of bacterial envelopes 28 
and reflect how nanomaterials/molecular transporters can interact with these envelopes, being 29 
the major aim of this review. The first part of this manuscript overviews the permeability of 30 
bacterial envelopes and how it limits the internalization of common antibiotic and novel 31 
oligonucleotide drugs. Subsequently we critically discuss the mechanisms that allow 32 
nanomaterials/molecular transporters to overcome the bacterial envelopes, focusing on the most 33 
promising ones to this end – siderophores, cyclodextrins, metal nanoparticles, 34 
antimicrobial/cell-penetrating peptides and fusogenic liposomes. This review may stimulate 35 
drug delivery and microbiology scientists in designing effective nanomaterials/molecular 36 
transporters against bacterial infections. 37 
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 90 
1. Introduction 91 
The ability to control infections with antibiotics has had a major impact on human and animal  92 
life over the last century [1]. However, the antibiotic era is threatened by resistance of bacteria 93 
to antibiotics and a very short pharmaceutical pipeline of new antibiotics [2]. Infections caused 94 
by resistant bacteria are already responsible for nearly 50 000 annual deaths in Europe and the 95 
United States [3, 4].   96 
  
The bacterial cell envelope is a sophisticated permeability barrier that can hinder the 97 
internalization/accumulation of antibiotics in bacterial cells, being a major cause of bacterial 98 
resistance to antibiotics [5]. Poor antibiotic internalization could be solved if antibiotics were 99 
“carried” into bacterial cells. Bacterial resistance to antibiotics can also arise from the 100 
expression of specific genes of resistance [6-8]. This could be solved by controlling gene 101 
expression in bacteria through antisense oligonucleotides [9]. However, oligonucleotides 102 
generally fail to be internalized in bacteria [10]. Nanomaterials and molecular transporters able 103 
to successfully interact with the bacterial envelopes are interesting to carry oligonucleotides 104 
and poorly internalized antibiotics across the bacterial envelope. Also, these carriers may 105 
prevent drug efflux from the bacterial cells, as intracellular delivery of a high dosage of drug 106 
into bacteria may overwhelm the efflux pumps [11, 12]. The efflux of antibiotics will not be 107 
detailed here since it has already been extensive reviewed [13-16]. Instead of serving as carriers 108 
of bactericidal drugs into bacteria, certain nanomaterials and peptides interact with the bacterial 109 
envelope so extensively that they can disrupt it, thus serving as bactericidal per se to replace 110 
antibiotics. Clearly, the potential of nanomaterials and molecular transporters to overcome the 111 
bacterial envelope depends on the ability of the materials/transporters to efficiently interact with 112 
the different bacterial envelopes.  113 
Nanomaterials and molecular transporters have been widely explored in mammalian cells 114 
which mostly take them up by endocytosis [17]. Differently, it is believed that bacteria do not 115 
endocytose (except a restricted group belonging to the phyla Planctomycetes [18]) and the use 116 
of nanomaterials/molecular transporters in bacteria is mostly based on a trial and error approach 117 
[1, 11, 12, 19-21]. An in-depth discussion on how the different layers of bacterial envelopes 118 
may be potential barriers is pivotal to boost the rational development of more efficient 119 
nanomaterials/molecular transporters in the combat of bacterial infections. Although there are 120 
some interesting reports on the recent use of nanomaterials to manage infections [1, 11, 12, 19-121 
  
21], to the best of our knowledge the interaction of nanomaterials with bacteria has never been 122 
addressed. 123 
In this review we first summarize the general structure of the bacterial envelope of Gram-124 
negative bacteria and Gram-positive bacteria of the typical Firmicutes phylum (Actinobacteria 125 
with a different cell wall, such as that of the genus Mycobacterium, Nocardia, Rhodococcus 126 
and Corynebacterium, are beyond the scope of this review). We then consider the permeability 127 
of these envelopes to external compounds and how it limits the internalization of common 128 
antibiotics and novel oligonucleotide drugs into bacteria. Subsequently, the nanomaterials and 129 
molecular transporters with potential to overcome the bacterial envelope, either by direct 130 
penetration or intracellular delivery of antibiotic/oligonucleotide drugs, are discussed. A special 131 
focus is given to the cell wall, i.e. the outermost layer of the bacterial envelope that determines 132 
the bacterial envelope permeability and the initial interaction with foreign compounds and 133 
materials. Seemingly much more research has been reported on the transport in Gram-negative 134 
bacteria compared to Gram-positive bacteria; nevertheless, this review aims for a global 135 
overview, including the relevant Gram-positive teichoic acids which are seldom considered. 136 
Finally, our conclusions and future perspectives are presented. 137 
 138 
 139 
2. Bacterial cell envelope barrier  140 
Bacteria, like mammalian cells, have their cytosol surrounded by a symmetric bilayer 141 
composed of amphiphilic phospholipids – the cytoplasmic membrane [22]. However, because 142 
they are unicellular organisms that often inhabit hostile environments, bacteria developed an 143 
extra cell wall that surrounds and protects the cytoplasmic membrane [23]. The cell wall 144 
provides protection against osmotic pressure and mechanical damage, while allowing 145 
permeation of key substrates for bacterial metabolism and communication with the environment 146 
  
[24, 25]. Together, the cell wall and the cytoplasmic membrane compose the bacterial cell 147 
envelope. The cell wall, in turn, is subdivided into different layers. There is often lack of 148 
precision in the field on the reference to the different bacterial envelope layers. In this section, 149 
these envelope layers and their permeability will be described for Gram-negative and Gram-150 
positive bacteria of the typical Firmicutes phylum, Figure 1 and 2. The permeability of these 151 
envelopes is overviewed according to the current knowledge (which is still limited), with a 152 
focus on the transport through the cell wall – the critical intake barrier. 153 
 154 
2.1 Gram-negative bacteria 155 
The cell wall of Gram-negative bacteria comprises the outer membrane (OM) and the 156 
periplasmic space composed of a thin layer of peptidoglycan, Figure 1 [26]. Since the OM is 157 
determinat to define the permeability to foreign compounds, a particular focus is given below 158 
to the OM. 159 
 160 
2.1.1 Outer membrane 161 
The OM is not a common phospholipid bilayer, but rather an asymmetric lipid bilayer – it 162 
is composed of phospholipids only in the inner leaflet and mostly lipopolysaccharide (LPS) in 163 
the outer leaflet [24, 27, 28]. In Gram-negative bacteria the major membrane phospholipid is 164 
phosphatidylethanolamine (PE), followed by phosphatidylglycerol (PG) and smaller amounts 165 
of cardiolipin [29, 30] (Figure 1). The LPS is a nonfluidic amphiphilic structure composed of 166 
three covalently-linked regions (Figure 1). LPS has a net negative charge, higher than the usual 167 
negatively-charged phospholipids, and it is held in position at the OM surface by divalent 168 
cations (Figure 1) [23, 24, 27]. The presence of LPS in the OM decreases its permeability to 169 
hydrophobic compounds (Figure 1) up to 50-100 times (as calculated from the oxidation’s rate 170 
of a steroid probe in the cytosol of Gram-negative bacteria with respectively intact and LPS-171 
  
deficient OM) [23, 24, 27, 31, 32]. Hydrophobic substrates that succeed in crossing the LPS are 172 
expected to become internalized into the cytosol by diffusion through the lipid bilayers of the 173 
outer and/or cytoplasmic membranes. In addition, the OM contains embedded proteins, mainly 174 
the outer membrane proteins (OMPs; which are integral proteins spanning the entire OM) and 175 
lipoproteins (LPs; which are mainly embeded in the cytoplasmic leaflet of the OM) (Figure 1) 176 
[23]. The function of LPs is not yet completely resolved, they may act as enzymes and 177 
transporters [33]. Differently, the OMPs form aqueous channels cucial for bacterial intake of 178 
nutrients [23]. 179 
OMPs can serve either as passive diffusion channels (general porins and specific channels) 180 
or active transporters (Figure 2).  181 
General porins (or simply porins), the most abundant proteins of the OM, allow the 182 
internalization of small hydrophilic substrates (including sugars, amino acids and ions) that are 183 
available in high concentrations and can thus passively diffuse down the concentration gradient 184 
through porins (Figure 2) [16, 34-37]. Porins do not bind the transported compounds; rather, 185 
porins are relatively unspecific and mostly discriminate their substrates by size, although charge 186 
may also play a role [28]. According to the crystallography studies on the better known classical 187 
porins (OmpF, OmpC and PhoE) present in Escherichia coli (E. coli), OmpF is typically 188 
considered the largest porin – a pore size of 0.7 nm and an exclusion limit of about 600 Da [16, 189 
28, 30]. OmpF allows the diffusion of both cationic and uncharged molecules, while OmpC is 190 
slightly cation selective, and PhoE is slightly anion selective [30, 38-41]. Another exceptionally 191 
large porin named OmpG (with a pore diameter of 1.5 nm that can be constricted to 0.8 nm) 192 
was later found to exist in E. coli (and other bacteria), but only in rather small amounts [42]. 193 
The Gram-negative species investigated so far possess general porins with a permeability 194 
mostly similar to that of the general porins of E. coli, except P. aeruginosa which has a 195 
  
significantly lower permeability since its major OMP channel (OprF) exists as an open channel 196 
only at very low levels [22, 28, 35, 43].  197 
Hydrophilic substrates needed for bacterial growth are not always available in sufficiently 198 
high concentrations to diffuse fast through general porins [30]. Thus, specific passive OMP 199 
channels exist that can bind substrates, with low affinities, in order to preferentially facilitate 200 
their passive diffusion (Figure 2) [34, 44]. They can also allow the unspecific flow of 201 
compounds, such as amino acids and carbohydrates, that are scarce in the environment [23, 28, 202 
36]. Like in general porins, transport through specific passive OMP channels is still driven by 203 
the concentration gradient and is thus energy-independent [34]. The best well-known specific 204 
channels are LamB and Tsx from E. coli [16, 36]. The LamB channel (which pore is 0.5-0.6 205 
nm in diameter) is dedicated to the transport of maltose and larger malto-oligosaccharides, 206 
which need to be first converted in a linear form to fit the LamB channel [23, 28, 36, 45]. In 207 
addition, ScrY, a channel homologous to LamB but larger (≈ 0.85 nm pore diameter) allows 208 
the specific transport of several sugars such as sucrose, in some E. coli and Salmonella strains 209 
[28, 30, 46].  The Tsx channel, on the other hand, is involved in the specific transport of 210 
nucleosides and deoxynucleosides; free bases or nucleoside monophosphates (nucleotides) are 211 
not internalized [30, 46]. Tsx has several distinct binding sites in the channel; the part that binds 212 
the base moiety of nucleosides is only 0.3-0.5 nm wide, but the part that binds the sugar moiety 213 
is 0.7-0.8 nm wide [46].  214 
Other noteworthy specific passive OMP channels were recently discovered that only open 215 
upon the presence of their substrate, without the need of energy, named ligand-gated channels 216 
(Figure 2). This way the passive diffusion of a cyclic oligosaccharide, which is too big to pass 217 
through the classical OMP passive channels, was found possible without linearization (needed 218 
for malto-oligosaccharides to cross LamB) [45]. In particular, α-cyclodextrin (α-CD), with a 219 
cylindrical bulky structure of 973 Da and an outer diameter of 1.37 nm, was internalized via 220 
  
the CymA channel in Klebsiella oxytoca (a species closely related to Klebsiella pneumoniae) 221 
which, in the open state, has a diameter of around 1.1-1.4 nm [47, 48]. Orthologues of CymA 222 
are present in the Enterobacteriaceae and Vibrionaceae, although the channel permeability has 223 
only been studied in Klebsiella oxytoca [47]. 224 
Another ligand-gated channel is dedicated to the transport of hydrophobic long fatty acids, 225 
therefore contradicting the general understanding that only molecules with a hydrophilic 226 
surface can diffuse through OMP channels [44, 49]. In particular, oleic acid, 283 Da, could be 227 
internalized by FadL channels, which are widespread among Gram-negative bacteria, but better 228 
studied for E. coli [44, 49]. Differently from hydrophilic compounds, the hydrophobic fatty 229 
acids are not transported across the membrane via the polar central part of the channels, but 230 
rather through a lateral opening (of 0.8 nm in diameter) from where the fatty acids diffuse 231 
laterally in the OM (Figure 2) [37, 44].  232 
Valuable hydrophilic substrates that are available only in extremely low amounts (such as 233 
micronutrients) need to be bound with high affinity by active (transport) OMPs to be 234 
internalized (Figure 2). The transport by such OMPs occurs against the concentration gradient, 235 
thus requiring energy expense [34]. Active OMPs, named TonB-dependent transporters 236 
(TBDTs), form large channels generally used for the uptake of iron complexes (normally up to 237 
1000 Da) and vitamin B12 (around 1355 Da) [34, 37]. TBDTs are present in much lower 238 
amounts than passive channels and only open when triggered by substrate binding, similarly to 239 
ligand-gated passive channels [23, 28, 47]. However, differently from ligand-gated diffusion 240 
channels, energy from the proton motive force (pmf) of the cytoplasmic membrane (as the OM 241 
is not energized) has to be transmitted to the TBDT to open the channel [47], which explains 242 
that the TBDT in the OM is part of a complex system that spans the envelope (Figure 1) [28, 243 
50]. For the active intake of iron, iron is typically in the form of complexes formed by iron 244 
chelating siderophores [50]. The siderophores are transported as a whole via the OM 245 
  
transporters into the periplasm where they bind to a periplasmic binding protein and only in the 246 
cytoplasm the iron is released from the complex [50, 51]. Also vitamin B12, containing a Co2+- 247 
ion in a corrin ring, is transported by bacteria as a whole [50]. Recently, it was found that besides 248 
iron and vitamin B12, the TonB-dependent transport can also be used to take up other substrates 249 
such as nickel and carbohydrates, but with much lower affinity [50]. Also colicins 250 
(proteinaceous toxins) can be taken up by TBDTs, as studied for colicin M transported via the 251 
TBDT named FhuA in E. coli – the only example of a protein import by E. coli [52]. The FhuA 252 
pore diameter is around 2.5 nm in the fully open state, while colicin M is 3 to 4 nm of diameter 253 
in the folded state, so it first needs to unfold to become (fully or partially) imported [52, 53]. 254 
 255 
2.1.2 Periplasm and cytoplasmic membrane 256 
Compounds that cross the OM will encounter the periplasmic space located in between the 257 
outer and cytoplasmic membrane (CM) (Figure 1) [27, 30]. The periplasm is crucial for cell’s 258 
structure maintenance, nutrition and protection against potentially harmful compounds [23, 24, 259 
27, 30]. As such, the periplasm is densely populated with transport proteins (involved in the 260 
transport of sugars, amino acids, vitamins and inorganic ions) and enzymes that degrade 261 
potentially harmful compounds and participate in envelope biogenesis (such as phosphatases, 262 
nucleases, proteases and β-lactamases) [23, 24, 27, 30]. Besides proteins, the periplasmic space 263 
possesses a high concentration of small molecules (such as amino acids, mono- and 264 
oligosaccharides and biosynthetic precursors and degradation products of peptidoglycan) which 265 
results in a space of significantly higher viscosity than the bacterial cytosol [24]. This gel-like 266 
periplasm can, therefore, considerably retard diffusion; protein diffusion was slowed down up 267 
to 3.5 times when compared to diffusion in the cytosol, as measured for the periplasmic and 268 
cytoplasmic green fluorescent protein in E. coli by fluorescence recovery after photobleaching 269 
[54].  270 
  
The periplasmic space comprises a thin layer of peptidoglycan (Figure 1). Peptidoglycan is 271 
a rigid polymer that provides structure, mechanical protection and osmoregulation [23, 24, 27]. 272 
It is a disaccharide composed of alternating units of N-acetylglucosamine and N-acetyl-273 
muramic acid cross-linked by short peptide chains with variable composition [23, 27]. These 274 
form a coarse mesh that will normally offer little resistance to diffusion [22, 30]. The 275 
peptidoglycan mesh pore size is similar in Gram-negative and Gram-positive bacteria and it is 276 
thought to be around 2-3 nm, as estimated for E. coli, B. subtillus and B. megaterium (Figure 277 
1) [55-57]. Using this pore size, it was calculated that peptidoglycan should be permeable to 278 
globular uncharged hydrophilic proteins up to 22-24 kDa and 50 kDa, respectively for 279 
unstretched peptidoglycan (isolated from bacteria) and stretched peptidoglycan (resembling 280 
growing bacterial cells) [56]. Nevertheless, doubts remain about the peptidoglycan 281 
permeability; moreover it is known that it can depend on the bacteria, the bacterial growth rate 282 
and the degree of peptidoglycan’s  cross-linking [58, 59]. For example, Helicobacter pylori was 283 
hypothesized to have a larger peptidoglycan’s mesh than E. coli [60].  284 
The periplasm covers the cytoplasmic membrane which, differently from the OM, is a 285 
symmetric phospholipid bilayer (Figure 1) [30]. The phospholipid composition in the 286 
cytoplasmic membrane is similar to that of the inner OM’s leaflet [23, 29, 30, 55]. Besides 287 
phospholipids, integral and peripheral proteins are also present in the cytoplasmic membrane 288 
[2]. These are either structural proteins or transport proteins involved in the passive or active 289 
transport of hydrophilic substrates into the cytosol [2]. For instance, most sugars such as 290 
maltose are carried by periplasmic proteins to the ATP-binding cassette (ABC) transporters in 291 
the cytoplasmic membrane [46]. For nucleosides transport, no periplasmic binding proteins are 292 
known and they are transported across the cytoplasmic membrane via the transporters NupC 293 
and NupG in E. coli mainly energized by the pmf [46, 61]. Differently, hydrophobic substrates 294 
  
will pass through the hydrophobic lipid bilayer of the cytoplasmic membrane into the cytosol 295 
by simple diffusion. 296 
 297 
2.2 Gram-positive bacteria 298 
The cell wall that covers the cytoplasmic membrane in Gram-positive bacteria is markedly 299 
different from that of Gram-negative bacteria (Figure 1). The Gram-positive cell wall is 300 
composed of teichoic acids and peptidoglycan, containing also proteins.  301 
The cell wall is decorated with considerable amounts of anionic polysaccharides – the 302 
teichoic acids – that are in contact with the outer environment [23, 30]. Teichoic acids in a 303 
certain way relate to LPS in Gram-negative bacteria. Due to their anionic charge they bind metal 304 
cations (mainly Mg2+, but also Ca2+ and K+), regulating the envelope’s rigidity and permeability 305 
[23, 30]. Teichoic acids are divided in wall teichoic acids (WTA), covalently attached to the 306 
peptidoglycan, and lipoteichoic acids (LTA), anchored to the head groups of the cytoplasmic 307 
membrane (Figure 1) [23, 62, 63]. Teichoic acids, in particular WTA, limit the permeation of 308 
hydrophobic compounds, in a similar way as LPS do but at a considerably lower extent [2, 23, 309 
27, 28, 30, 34, 62].  310 
The peptidoglycan in Gram-positive bacteria is similar in structure and porosity to that in 311 
Gram-negative bacteria [23, 24, 30]. However, to compensate the absence of an OM, in Gram-312 
positive bacteria the peptidoglycan layer is significantly thicker and thus much more resistant 313 
to mechanical stress [23, 24, 30]. The thicker peptidoglycan layer can also retard the access of 314 
foreign compounds to the cytoplasmic membrane. 315 
The Gram-positive’s cell wall also comprises proteins, bound to the teichoic acids, the 316 
peptidoglycan, or the cytoplasmic membrane [23, 30, 64]. These proteins can be similar to the 317 
ones found in the periplasm of Gram-negative bacteria, being involved in defense, transport, 318 
  
synthesis and turnover of peptidoglycan, adhesion to other bacteria and to their host for 319 
infection [23, 30, 64].  320 
The cytoplasmic membrane of Gram-positive bacteria is similar to that of Gram-negative 321 
bacteria, differing only in the relative phospholipid composition – Gram-positive bacteria 322 
generally posess a lower amount of PE and a higher amount of PG than Gram-negative bacteria 323 
(Figure 1)  [55, 65]. Besides PE and PG, smaller amounts of cardiolipin and eventually 324 
phosphatidylserine are also present [55, 65]. Like in Gram-negative bacteria, the cytoplasmic 325 
membrane contains peripheral and integral proteins, as well as passive and active protein 326 
channels for the internalization of hydrophilic compounds into the cytosol [2]. This includes 327 
the active transport of iron complexes, where a protein anchored on the cytoplasmic membrane 328 
(resembling the Gram-negative periplasmic binding protein) first binds the extracellular iron-329 
siderophores and an ABC transporter brings the complex into the cytosol using ATP (Figure 1) 330 
[51]. Hydrophobic substrates, on the other hand, diffuse passively through the lipids of 331 
cytoplasmic membrane bilayer into the bacterial cytosol. 332 
 333 
  
 334 
Figure 1. Structure and permeability of the bacterial envelope of Gram-negative and Gram-335 
positive bacteria of the typical Firmicutes phylum. Note that the TBDT transporter in the OM 336 
of Gram-negative bacteria is part of a complex system that spans the envelope, composed of (i) 337 
a specific TBDT at the OM that binds the substrate, (ii) the TonB complex (comprising the 338 
TonB protein at the periplasmic space and ExbB and ExbD proteins at the cytoplasmic 339 
membrane) that transduces the pmf of the cytoplasmic membrane for the conformational change 340 
of TBDT, (iii) a protein in the periplasm (light purple circle on top of the ‘ABC transp’) that 341 
captures the substrate that flows from the open TBDT channel and (iv) an ATP-binding cassette 342 
(ABC) transporter that transports the substrate across the cytoplasmic membrane using ATP 343 
  
[28, 50]. Also, LPS in Gram-negative bacteria is represented with its three regions: the lipid A 344 
(a lipid with a large number of saturated fatty acids), the core polyssacharide (a complex anionic 345 
oligosaccharide) and the O-antigen (a specific O-polysaccharide that differs between bacteria 346 
and can be highly antigenic) [22, 23, 27, 30]. LPS and teichoic acids are represented with their 347 
net negative charge (yellow circles) and the divalent cations attached (blue circles); the number 348 
of circles depicted are not representative and the divalent cations occur regularly along the LPS. 349 
Note that the peptidoglycan layer should be about 1.5-7 nm thick in Gram-negative bacteria 350 
[66, 67] and about 15-100 nm thick in Gram-positive bacteria [23, 67], while the peptidoglycan 351 
mesh is equally wide (2-3 nm) in both Gram types [55-57]. The thickness of LPS and 352 
periplasmic space in Gram-negative bacteria are believed to be 7-40 nm and 13-25 nm, 353 
respectively [27, 30, 68-70].  354 
TBDT: TonB-dependent transporter; pmf: proton motive force; ABC transp: ATP-binding 355 
cassette transporter involved in the active iron uptake; LPS: lipopolysaccharide; PE: 356 
Phosphatidylethanolamine; PG: Phosphatidylglycerol. 357 
 358 
 359 
  360 
  
 361 
Figure 2. Channels formed by outer membrane proteins (OMPs) in Gram-negative bacteria. 362 
These can be passive diffusion channels, formed by general porins and specific channel, and 363 
active transporters, formed by TonB-dependent transporters (TBDTs). The diameter of the 364 
pores in the channels and the respective molecular weight exclusion (based on the substrates 365 
known to penetrate those channels) are presented. Specific channels are indicated in italic. 366 
 367 
 368 
3. The bacterial cell envelope limits internalization of antibiotics and 369 
antibacterial oligonucleotides 370 
The bacterial cell envelope and in particular the cell wall are stringent barriers that can 371 
significantly restrict and even completely hinder the penetration of anti-infective drugs into 372 
bacterial cells. In the subsequent sections it is discussed how the bacterial envelopes of Gram-373 
negative and -positive bacteria may pose a barrier to traditional antibiotics (3.1) and to novel 374 
(antibacterial) oligonucleotides (3.2). 375 
 376 
3.1 Internalization of antibiotics 377 
  
Antibiotics may act at the bacterial envelope or in the bacterial cytosol [71, 72]. At the 378 
bacterial envelope, the peptidoglycan is a common target; the peptidoglycan’s biosynthesis can 379 
be inhibited by β-lactam antibiotics (including penicillins, monobactams, cephalosporins and 380 
carbapenems) and glycopeptide antibiotics (vancomycin being the most common one) [73-75]. 381 
Intracellularly, antibiotics can target (i) DNA/RNA synthesis, as is the case of quinolones (e.g. 382 
ciprofloxacin), ansamycins (e.g. rifamycin), actinomycins, novobiocin and albicidin, (ii) 383 
protein synthesis, as is the case of tetracyclines, nitrofurans, macrolides (e.g. clarithromycin 384 
and erythromycin), aminoglycosides (e.g. tobramycin, streptomycin, kanamycin, gentamicin 385 
and amikacin), chloramphenicol, or fusidic acid and (iii) folate synthesis, being the case for 386 
sulphonamides and trimethoprim [71, 76].  387 
Teichoic acids in Gram-positive bacteria and LPS in Gram-negative bacteria restrict the 388 
permeation of hydrophobic antibiotics (Figure 3a) [27, 28, 30, 62]. In particular, LPS can hinder 389 
the penetration of macrolides, rifamycins, novobiocin, or fusidic acid, contributing to the 390 
resistance of Gram-negative bacteria to these antibiotics (Figure 3b) [35, 72, 77, 78]. The 391 
peptidoglycan is generally believed not to be a significant barrier for the permeation of 392 
antibiotics [22]. Some antibiotics, such as aminoglycosides, may also “force” their penetration 393 
into bacteria by disturbing the bacterial cell wall, a mechanism known as "self-promoted 394 
uptake" [28]; studies on Gram-negative bacteria indeed suggest that these antibiotics may 395 
compete with divalent cations for binding to LPS, thus destabilizing LPS and forcing their own 396 
penetration [28]. 397 
After crossing the teichoic acids/LPS, the majority of antibiotics that are able to reach the 398 
cytosol do so by passive diffusion [36]. Only a minority of antibiotics, such as tobramycin, may 399 
be actively transported across the OM (Figure 3a and 3b) [36, 79]. Also 0.8 kDa rifamycin and 400 
1 kDa albomycin (albomycin is comprised of an antibiotic moiety naturally covalently linked 401 
to Fe3+-siderophores) are known to use the active TBDT channel named FhuA [36, 80]. 402 
  
Passive diffusion of antibiotics can either occur (i) across the lipid bilayers of bacterial 403 
membranes – being the case for most antibiotics (e.g. novobiocin, macrolides, tetracyclines and 404 
quinolones), since they have some degree of hydrophobicity, or (ii) across the Gram-negative 405 
OM’s general porins and specific passive channels – being the case for the small hydrophilic 406 
antibiotics (such as ampicillin, amoxicillin, chloramphenicol, carbapenems, tetracyclines and 407 
quinolones), Figure 3b [16, 28, 35, 36]. Quinolones and tetracyclines, depending on the pH, 408 
may exist in an uncharged or charged form, respectively crossing the OM via lipid mediated 409 
diffusion or via the porins (Figure 3b) [28, 35, 81]. Penicillins, such as the zwitterionic 410 
ampicillin and amoxicillin, can be translocated via the general porin OmpF in E. coli; however, 411 
OmpF prevents anionic penicillins as carbenicillin to translocate, due to electrostatic repulsion 412 
between the anionic residues in the OmpF channel and the antibiotic [35, 82]. The carbapenem 413 
imipenem can also use the general OmpF to penetrate E. coli and the specific OprD channel 414 
(which uptakes basic amino acids and peptides structurally similar to this carbapenem 415 
molecule) in P. aeruginosa [38]. Albicidin, a relatively high molecular weight (∼850 Da) 416 
antibiotic, can passively diffuse through the Gram-negative Tsx specific channel [36, 46]. 417 
Nevertheless, the size filtering effect of the OMP channels hinders or severally retards the 418 
diffusion of bigger hydrophilic antibiotics, as it is the case for glycopeptides like e.g. 419 
vancomycin (molecular weight of 1450-1500 Da) (Figure 3b) [22, 72, 74]. These antibiotics, 420 
together with lipophilic antibiotics which influx is restricted by LPS (as described above), are 421 
thus only active against Gram-positive bacteria (Figure 3b) [72]. Therefore, Gram-negative 422 
bacteria are intrinsically resistant to several antibiotics and among Gram-negative bacteria P. 423 
aeruginosa has a particularly low permeable OM [22, 28]. In addition, functional change or 424 
loss/significant reduction in the number of expressed porins in Gram-negative bacteria can 425 
further decrease the OM’s permeability to antibiotics [35, 83]. Moreover, even antibiotics able 426 
to permeate the bacterial envelope in Gram-negative and -positive bacteria can become 427 
  
inactivated by bacteria expressing specific genes of resistance that code for enzymes that 428 
modify/degrade the antibiotic, or for a competitive inhibitor of the antibiotic or for altered forms 429 
of the antibiotic’s substrate [6, 72]. This antibiotic resistance crisis demands for novel 430 
antibacterial therapies. 431 
 432 
3.2 Internalization of antibacterial oligonucleotides 433 
To respond to the antibiotic crisis, antisense oligonucleotides could become a promising 434 
alternative as new antimicrobials. They act by specifically hybridizing in situ with 435 
complementary bacterial RNA and can, consequently, inhibit the expression of selected genes 436 
[10, 84, 85]. These can be essential bacterial genes, thus preventing bacterial growth, or genes 437 
involved in the resistance to antibiotics, hence restoring susceptibility of bacteria to antibiotics. 438 
This strategy could thus provide a potentially endless source of active antibacterials. Even if 439 
the bacterial target undergoes a point mutation that renders the oligonucleotide inactive, the 440 
oligonucleotide can be easily redesigned to become an effective drug again. 441 
Among oligonucleotides, nucleic acid mimics (NAMs) are especially interesting, as, 442 
contrary to traditional DNA oligonucleotides, NAMs are composed of modified DNA or RNA 443 
sugars that make them resistant to endonuclease’s degradation and improve their affinity 444 
towards RNA targets [86-89]. In particular, the charge neutral NAMs peptide nucleic acids 445 
(PNA) and phosphorodiamidate morpholino oligomers (PMO), as well as the negatively 446 
charged NAMs locked nucleic acids (LNA) and 2’-OMethyl RNA (2’OMe) are promising to 447 
target bacteria (Figure 4) [90-98]. These can be further modified on the backbone by including 448 
phosphorothioate internucleotide linkages (PS), instead of the normal phosphodiester linkages 449 
(PO), further improving the stability and affinity (Figure 4)  [99, 100]. 450 
The improved affinity of NAMs towards the target RNA, compared to traditional 451 
oligonucleotides, allows the design of shorter NAMs sequences [99, 101] which in turn may 452 
  
lower their penetration’s restraint into bacteria. Actually, decamers PS-LNA/2’OMe were seen 453 
to be able to target H. pylori cells adhered on a slide [97] and undecamers bactericidal PMO 454 
could reduce the growth of E. coli in pure culture and in an infected mice, although growth 455 
recovery was observed after 4h in vitro and 12h in vivo with multiple doses necessary to sustain 456 
the growth reduction [96]. Also, heptadecamers LNA/DNA were found to penetrate E. coli, but 457 
a very long incubation of 18h was performed and still only 14% of the bacteria showed 458 
association with the LNA/DNA [92]. Clearly, internalization of NAMs in bacteria may happen, 459 
depending on the specific bacteria and on the NAM’s structure, through currently unresolved 460 
mechanisms. However, internalization of oligonucleotides into bacteria is generally poor and 461 
insufficient to eradicate bacteria. Thus, although NAMs may solve the stability and affinity 462 
issues of natural oligonucleotides, penetration into bacteria remains a major bottleneck of 463 
antisense based antibacterial therapy [10, 95, 102, 103].  464 
Very few studies investigated so far the role of the individual bacterial envelope structures 465 
in the restricted internalization of nucleic acids in bacterial cells. Studies using the neutrally 466 
charged PNA in E. coli showed that the OM is the rate limiting layer in the kinetics of PNA 467 
penetration [90]. The LPS, in particular, was suggested to be a major barrier for PNA 468 
penetration into E. coli [84], probably due to the relatively high hydrophobicity of PNA, 469 
compared to charged oligonucleotides (Figure 3a). After the OM, PNA needs to cross the 470 
peptidoglycan. Good et al. observed that antibiotics, which block peptidoglycan formation, did 471 
not improve PNA potency against E. coli and thus inferred that the peptidoglycan is not a barrier 472 
for PNA penetration [84]. However, this might not be the case for all bacteria. Studies using 473 
PNA to hybridize in different bacteria suggested that thick peptidoglycan layers from Gram-474 
positive bacteria, such as Bacillus cereus (which has a peptidoglycan 6-7 times thicker than that 475 
of E. coli [67]), may significantly retard PNA penetration (Figure 3a) [104, 105].  476 
  
For negatively charged NAMs (Figure 4) to cross the OM, they need to overcome the 477 
presumable electrostatic repulsion to the negatively charged LPS and the size filtering effect of 478 
OMPs (Figure 2). Most used NAMs have a molecular weight of about 2-4 kDa [10, 91]. 479 
Therefore, passive diffusion of the NAMs through the OM is highly unlikely, considering the 480 
size exclusion of porins to be 0.7-0.8 nm in diameter and 600 Da in molecular weight (Figure 481 
3a, left pannel) [106]. Even if specific passive channels and active TBDT channels could 482 
accommodate the NAMs despite being structurally very different to their substrates, these 483 
channels would still be most of the times too narrow for NAMs translocation (Figure 2 and 3a). 484 
Therefore, the potential of oligonucleotides in general, and NAMs in particular, as novel 485 
antibacterial drugs to solve the antibiotic crisis can only be fulfilled if oligonucleotides become 486 
“carried” across the bacterial envelope. 487 
 488 
 489 
  
 490 
Figure 3. a) Limited permeability of the bacterial cell envelope of Gram-negative and -positive 491 
bacteria to oligonucleotides and common antibiotics. The depicted oligonucleotides include neutral 492 
oligonucleotides (NAMs such as PNA and PMO) and negatively charged oligonucleotides (DNA 493 
and NAMs such as LNA and 2’OMe). The antibiotics are represented as circles: yellow and orange 494 
circles – antibiotics that can be internalized; brown and red circles – antibiotics that cannot penetrate. 495 
The antibiotics identified as hydrophilic (brown and yellow circles) are too hydrophilic for diffusion 496 
through the lipid bilayers, contrary to the hydrophobic antibiotics (red and orange circles). On the 497 
  
Gram-positive bacteria, the cross on top of the wall teichoic acids should be considered as hampered 498 
penetration by teichoic acids in general (lipoteichoic acids and wall teichoic acids). b) Summary of 499 
the main internalization routes in Gram-negative bacteria that allow or hamper the influx of relevant 500 
antibiotics, based on the antibiotic’s lipophilicity and size (as indicated by the approximate 501 
molecular weight of the exemplified antibiotics) [35, 72, 77, 78]. The internalization of hydrophilic 502 
antibiotics can be further hampered if the expression of OMP channels in bacteria is modified or 503 
suppressed [35, 83]. The envelope structures depicted are identified in Figure 1.  504 
 505 
 506 
 507 
Figure 4. Chemical structure of the most studied nucleic acid mimics (NAMs). LNA: locked 508 
nucleic acids; 2’OMe: 2’-OMethyl RNA; PNA: peptide nucleic acid; PMO: 509 
phosphorodiamidate morpholino oligomer. The sugar modifications are circled in yellow and 510 
the internucleotide linkage modification (phosphorothioate instead of the natural 511 
phosphodiester linkage) is circled in blue. 512 
 513 
 514 
  
4. Behaviour of nanoparticles and molecular transporters at the bacterial cell 515 
envelope 516 
There is a growing interest in nanoparticles (NPs) and molecular transporters to mediate the 517 
delivery of antibiotics/oligonucleotides in bacteria [20]. Also, certain NPs and peptides have 518 
bactericidal potential per se and have thus gained attention to replace antibiotics [12]. However, 519 
so far the exploration of NPs and molecular transporters (or carriers) to these ends has mostly 520 
relied on a trial and error approach. Clearly, to better understand the potential of NPs and 521 
carriers to overcome the bacterial envelope a ´dialogue´ between nanotechnologists and 522 
microbiologists is highly needed.  523 
 524 
4.1 Siderophores as ‘trojan horses’ for antibacterial drugs  525 
As mentioned in the section 2, siderophores are low molecular weight compounds, secreted 526 
by bacteria under iron-limited conditions, which have a high affinity for Fe(III) ions and are 527 
actively transported as a complex into the bacterial cytosol [107, 108]. Thus, conjugation of 528 
antibacterial drugs to siderophores holds the potential to allow active uptake by bacteria, so that 529 
siderophores can be used as ‘trojan horses’ for antibacterial drugs (Figure 5). This idea arose 530 
from sideromycins, a group of antibiotics formed by analogues of bacterial siderophores linked 531 
to low molecular weight metabolic inhibitors, which are taken up by the iron transport system 532 
and release the antibacterial inhibitor upon internalization [107]. Therefore, several compounds 533 
containing a catechol/hydroxamate siderophore analogue linked via a stable linker to β-lactams 534 
or vancomycin or via a cleavable linker to fluoroquinolones or macrolides have been tested 535 
against Gram-negative and -positive bacteria [107, 108]. Synthesized catecholate-type 536 
siderophores linked to β-lactams (ampicillin, amoxicillin, cephalexin and cefaclor) 537 
demonstrated high activity against the Gram-negative P. aeruginosa, Stenotrophomonas 538 
maltophilia, E. coli, K. pneumoniae and Serratia marcescens [109, 110]. For instance, the 539 
  
siderophore conjugated ampicillin increased the potency of free ampicillin up to 2000-fold in 540 
P. aeruginosa and Stenotrophomonas maltophilia, 500-fold in Serratia marcescens, 62-fold in 541 
K. pneumoniae and 15-fold in E. coli [110]. BAL30072, a β-lactam with a siderophore 542 
mimicking moiety (for the structure the reader is referred to [111]), also showed interesting 543 
results against several Gram-negative bacteria, including multi-resistant and impermeable 544 
bacteria as Burkholderia pseudomallei, P. aeruginosa and Acinetobacter baumannii in vitro 545 
[111-114]. The in vitro potency of BAL30072 compared to free β-lactam antibiotic comparators 546 
was found to be up to 30-375 times, 47 times and 8 times higher respectively against strains of 547 
B. pseudomallei, Acinetobacter Baumannii and P. aeruginosa [111-114]. These encouraging 548 
results led BAL30072 to enter clinical trials (Basilea Pharmaceutica Ltd.) [115, 116].  549 
Although to the best of our knowledge it has never been tested, siderophores may not be an 550 
efficient ‘trojan horse’ for the uptake of antibacterial oligonucleotides, considering that 551 
oligonucleotides are around 2-5 times bigger than sideromycins and also larger than the pore 552 
size of iron transporters in E. coli OM (as discussed in section 3.2). Nevertheless, since our 553 
knowledge on the OM permeability is limited it may be worth to investigate. 554 
 555 
4.2 Cyclodextrins as ‘trojan horses’ for antibacterial drugs  556 
As described in section 2, bulk cyclodextrins (CD) are able to diffuse through the CymA 557 
channel in Klebsiella oxytoca; orthologues of CymA were also found in Enterobacteriaceae and 558 
Vibrionaceae [47]. Therefore, cyclodextrins may hold potential as ‘trojan horses’ for 559 
antibacterial drugs (Figure 5). Cyclodextrins (typically 1.4 to 1.8 nm of outer diameter [117]) 560 
are investigated for nearly 70 years as drug carriers to improve the bioavailability, stability and 561 
solubility of drugs targeted to mammalian cells [117, 118]. They form water soluble cyclic 562 
oligosaccharides with an hydrophobic cavity that can enclose hydrophobic antibiotics via 563 
noncovalent interactions [119]. β-CD and its derivatives have been used for the inclusion or 564 
  
association of several antibiotics, such as macrolides, ryfamycins, quinolones, β-lactams, 565 
cephalosporins and tetracyclines, improving the antibiotic potency against Gram-negative 566 
bacteria such as E. coli, P. aeruginosa, Citrobacter spp, Enterobacter spp, Klebsiella spp and 567 
A. baumannii, and Gram-positive bacteria such as S. aureus [119-124]. For instance, when 568 
tested in Staphylococcus spp, Klebsiella spp, Escherichia coli, Pseudomonas aeruginosa, 569 
Enterobacter spp and Citrobacter spp, β-CD carriers decreased the minimum inhibitory 570 
concentration (MIC) of ampicillin and amoxicillin up to 4 times and the MIC of cefadroxil up 571 
to 16 times [121]. Besides improving the antibiotic’s stability and solubility, β-CD (and its 572 
derivatives) were considered to mediate enhanced permeation of the antibiotics [119-123]. In 573 
particular, it has been hypothesized that β-CD may drive internalization of the β-CD-antibiotic 574 
complex possibly via (i) CymA orthologue channels, (ii) enhaced adhesion to the bacterial 575 
surface (including pore channels) with potential local release of the antibiotic, and (iii) via 576 
destabilization of the bacterial envelope [120-123]. Also, β-CD capping silver NPs (AgNPs) 577 
improved their interaction at the bacterial envelope of E. coli, P. aeruginosa and S. aureus and 578 
enhanced the intracellular delivery of antibacterial silver ions [125]. 579 
The potential of CDs as drug carriers into bacterial cells can be restricted by poor colloidal 580 
stability of CDs which may result in the formation of aggregates of tens to hundreds of 581 
nanometers [119, 122, 123, 126]. Despite being less colloidaly stable than  α-CD and γ-CD, β-582 
CD is by far the most used CD carrier in drug delivery [127]. β-CD’s can be modified to become 583 
more stable, as seen for instance for (2-Hydroxypropyl)-β-CD and for PEGylated CDs [25, 584 
127]. Nevertheless, theoretical studies on the CymA channel (section 2.2.1) suggested that even 585 
colloidally stable β-CD may be too large to be efficiently internalized in bacteria via CymA 586 
[48]. Differently, the smaller α-CD can better flow through CymA [48]. Therefore, α-CD would 587 
theoretically be a better ‘trojan horse’ for bacteria than β-CD. However, the narrow 0.47–0.53 588 
nm cavity of α-CD limits the enclosure of most antibiotics [117, 119]. Further studies on the 589 
  
structure of CymA’s orthologue channels and the transport of different CDs in various bacteria 590 
may help elucidate the chances of CDs to penetrate bacteria with associated antibiotics. 591 
Concerning antibacterial oligonucleotides, they cannot be carried into the CD’s cavity due 592 
to its hydrophobicity. CDs can instead be associated with cationic polymers to electrostatically 593 
complex the negativaly charged oligonucleotides [117], but this would probably hamper CD’s 594 
mediated uptake. Hence, similarly to siderophores, CDs may be promising to carry low 595 
molecular weight antibiotics, but not oligonucleotides. 596 
 597 
 598 
4.3 Metal NPs to disrupt and penetrate the bacterial envelope  599 
Metals NPs (1-100 nm) like silver, gold, zinc oxide and titanium dioxide NP can have 600 
antibacterial properties against Gram-negative and -positive bacteria [20, 25]. The antibacterial 601 
effect of metal NPs depends on their ability to interact with the bacterial envelopes. For most 602 
antibacterial metal NPs this interaction results in letal disruption of the bacterial cell wall and/or 603 
the cytoplasmic membrane [6, 12, 20, 25]. For some antibacterial metal NPs, this interaction 604 
allows the internalization of metal NPs, so that these are letal by acting on the bacterial cytosol, 605 
targeting RNA, DNA and proteins [6, 12, 20, 25]. The antibacterial properties of metal NPs are 606 
long known, but how they interact with the bacterial envelope remains rather unclear [1, 128, 607 
129]. Their action depends on the NP’s size, concentration, shape, surface, charge and the 608 
capping agents used for stabilisation (which may affect the NP’s surface charge), as well as on 609 
the type of bacteria [20, 129, 130]. 610 
 611 
4.3.1 Interactions of metal nanoparticles with the bacterial cell envelope 612 
The interaction of metal NPs with the bacterial cell wall has been mostly studied for AgNPs 613 
and it is frequently suggested to be driven by electrostatic attractions between the positively 614 
  
charged NPs and the negatively charged bacterial envelope surface – probably the LPS in Gram-615 
negative bacteria and the teichoic acids in Gram-positive bacteria (Figure 5) [25, 131-133]. 616 
However, this does not seem to be a prerequisite since negatively charged AgNPs (diameter 617 
from 5 to 20 nm) were also shown to interact at the cell envelope of Gram-negative and -positive 618 
bacteria [134-136]. Negatively charged NPs were proposed to interact with metals bound to the 619 
LPS in the Gram-negative cell wall (see Figure 1), causing metal depletion and thus perturbing 620 
the assembly of LPS and compromising the OM’s permeability [135, 137]. Likewise, it is 621 
conceivable that anionic metal NPs could also interact with metals bound to teichoic acids in 622 
the Gram-positive cell wall. Still, anionic AgNPs were considerably less toxic than cationic 623 
AgNPs against Gram-positive Bacillus species [136].  624 
Besides electrostatic effects, binding of NPs to certain groups at the bacterial envelope 625 
surface has been suggested as well; for instance AgNP have a high affinity towards thiol groups 626 
and their antibacterial action was blocked by thiol containing agents [128, 138].  627 
Cell wall’s disturbance may be further aided by the formation of pores, called ‘pits’, by metal 628 
NPs (Figure 5), as proposed for AgNP [132, 139, 140]. Such ´pits´ may be breaks in the OM, 629 
including LPS – as reported for 5 nm AgNPs against the Gram-negative E. coli [139] – or on 630 
the peptidoglycan bonds between N-acetylglucosamine and N-acetyl-muramic acid – as 631 
suggested for 18 nm AgNP against the Gram-positive S. aureus [140].  632 
Some authors discuss that the extent of metal NP interaction at the cell wall may depend on 633 
the bacteria Gram type. Several studies report that the thicker peptidoglycan layer in Gram-634 
positive bacteria may render them more resistant to metal NPs [135, 140, 141]. However, the 635 
opposite has also been reported [130, 131, 133, 142]. Thus, the different Gram cell wall does 636 
not solely explain the interaction of metal NP on bacteria, but clearly the effect is strain 637 
dependent as well [142]. 638 
  
Overcoming the cell wall, metal NPs that reach the cytoplasmic membrane may disturb it 639 
directly by the formation of ‘pits’ similar to the ones formed in the cell wall (Figure 5). Indeed, 640 
AuNPs (2-29 nm of diameter) and PtNPs (2-19 nm of diameter) caused substantial cell wall 641 
and cytoplasmic membrane disruption in Salmonella enteritidis and Listeria monocytogenes 642 
[143]. Catechin-CuNPs (5.3 nm of average diameter) were also seen to cause separation of the 643 
cytoplasmic membrane from the cell wall, in S. aureus [133]. 644 
In addition, metal NPs can disturb the CM by interfering with the ATP balance and pmf 645 
gradient, eventually causing cell leakage (Figure 5) [6, 12, 132, 133, 144]. Vardanyan et al. 646 
verified that 3-15 nm anionic AgNPs increased ion flux across E. coli and Enterococcus hirae 647 
(E. hirae) [130]. Morever, the CM’s ATPase activity in E. hirae was decreased and the coupled 648 
H+ flux, as well as the associated H+-K+ exchange, were affected [130]. Upregulation of several 649 
OMPs (as OmpA, OmpC, OmpF) with accumulation of their precursors in the cytoplasm was 650 
also found as a consequence of pmf/ATP gradient dissipation in E. coli exposed to 9.3 nm 651 
AgNPs – without energy, OMP precursors cannot be translocated to the cytoplasmic membrane, 652 
therefore remaining in the cytoplasm [138].  653 
 654 
4.3.2 Evidence for internalization of metal nanoparticles in bacteria  655 
There are several reports on internalized AgNPs, CuNPs, PtNPs, ZnO NPs, TiO2 NPs, MgO 656 
NPs [128, 133, 134, 143, 145-149]. It is frequently difficult to evaluate how NPs penetrated the 657 
bacterial envelope, because several reports use bactericidal concentrations [128, 133, 143] and 658 
so NP’s penetration may be a consequence of their toxicity. Therefore, we only focus on 659 
published results obtained at a non-bactericidal concentration of metal NPs. It was found that 660 
1-1.5 mM ZnO NP (14 nm of diameter) were able to be internalized in E. coli and even increase 661 
the number of E. coli colonies, probably because bacteria can metabolize Zn2+ as an 662 
oligoelement [147]. Anionic ZnO and TiO2 NPs up to 70 nm were also suggested to penetrate 663 
  
the Gram-negative Salmonella Typhimurium (as tested by flow cytometry and TEM) and be 664 
transmitted to daughter bacteria, while bigger NP agglomerates adhered to the bacterial 665 
envelope [148]. Similarly, AgNPs (normally anionic, as produced by citrate and borohydride 666 
reduction [146, 150]) up to 80 nm were found to penetrate live Gram-negative P. aeruginosa 667 
with bigger NPs remaining mostly adhered on the bacterial surface [145, 151]. In live Gram-668 
positive B. subtilis, AgNPs from 8 to 33 nm [146] and even from 84 to 100 nm were reported 669 
to be internalized as well [152]. The majority of these NPs are clearly much larger than the 670 
reported pore sizes of the bacterial envelopes (as shown in Figure 1, 2 and 5). The penetration 671 
of these NPs on live bacteria may be aided by non-specific mild envelope perturbation including 672 
transient ‘pit’ formation [147], while keeping bacteria viable (Figure 5). Alternatively, 673 
passive diffusion has been considered for the influx of the ZnO and TiO2 NPs up to 70 nm (in 674 
Gram-negative bacteria) [148] and of AgNPs up to 80 nm (in Gram-negative and -positive 675 
bacteria) [146, 152]. However, it was reported that not all internalized AgNPs remained inside, 676 
but some were actively exported from P. aeruginosa and B. subtilis by active transporters 677 
(typically involved in antibiotics efflux); bigger AgNPs were more quickly exported while 678 
smaller AgNPs remained longer inside bacterial cells [145, 146, 152]. These studies on AgNPs 679 
transport were performed in live bacteria to assess real-time transport of AgNPs in and out of 680 
bacteria, using a method based on the size-dependent localized surface plasmon resonance 681 
(LSPR) spectral colors of single AgNPs by dark-field optical microscopy and spectroscopy 682 
[151]. The authors used this LSPR-based microscopy to distinguish internalized AgNPs from 683 
AgNPs extracellularly adhered to the bacterial envelope based on the scattering intensity of the 684 
AgNPs – intracellular NPs appear blurry and with lower scattered intensity, while extracellular 685 
NPs look sharper and brighter (due to the additive scattering of the bacterial membrane) [145, 686 
146, 152]. Looking only at the microscopy images, it is not straightforward to visually 687 
discriminate envelope adhered and internalized AgNPs [146]. Nevertheless, the presented 688 
  
method was initially validated by transmission electron microscope (TEM) [145, 151]. Still, it 689 
is intriguing that such NPs could diffuse through bacterial active and passive channels despite 690 
being up to 10-50 times larger than the respective channel’s pores (Figure 2 and 5). The authors 691 
argue that this should be due to an enormous ability of the channel’s pores to adapt their 692 
permeability in live conditions, something that can be overlooked in the crystallography 693 
analysis of the protein channels normally used to establish the pore sizes of the bacterial 694 
channels [145]. Clearly this is an unresolved issue that needs to be further investigated; we 695 
anticipate that the development of microscopy techniques with improved resolution will help 696 
to directly visualize in real-time NPs internalization in live bacteria, in the future. 697 
 698 
4.4 Carbon nanostructures, dendrimers and chitosan nanoparticles to disrupt and 699 
penetrate the bacterial envelope 700 
Although their interactions with the bacterial envelope have been less studied, NPs other 701 
than metal NPs like carbon nanostructures (as  carbon nanotubes and graphene oxide 702 
nanoparticles), chitosan NPs and dendrimers may overcome the bacterial envelope as well 703 
[153]). However, their internalization in bacteria without disruption of the bacterial envelope 704 
has never been reported to our knowledge. Differently, they all have potential to overcome the 705 
bacterial envelope by disrupting it [12, 20] (Figure 5). Therefore, they have been used against 706 
Gram-positive and -negative bacterial infections; while carbon nanostructures (CNS) have been 707 
mostly used as antimicrobials per se [154-157], dendrimers and chitosan NPs have been used 708 
both alone and as carriers of antibiotics [158-164].  709 
When used in lower concentrations, dendrimers (mostly polyamidoamine (PAMAM) 710 
dendrimers), and chitosan NPs, may serve as non-bactericidal reservoirs which can improve 711 
antibiotic’s half-life, bioavailability and biodistribution [158, 159, 161, 162]. In addition, they 712 
  
may also perturb the bacterial envelope making it somewhat more permeable which eventually 713 
improves the delivery of the antibiotic once it has been released from the NPs [160, 165]. 714 
At higher concentrations, the perturbation caused by dendrimers and chitosan NPs can be 715 
irreversible and lead to bacteria’s disruption [163-165]. This bactericidal effect arises from the 716 
NPs highly positive surface charge which promotes electrostatic adsorption of the NPs to the 717 
negatively charged bacterial surface, with possible displacement of the metal cations bound to 718 
LPS/teichoic acids, and induces permeabilization of outer and cytoplasmic membrane, leakage 719 
of cytosolic contents and bacteria disruption (Figure 5) [6, 11, 12, 165].  720 
Carbon nanostructures (CNS), such as carbon nanotubes (CNTs) and graphene nanosheets, 721 
have recently gained increased attention as antimicrobials [1]. Their needle-like shape, small 722 
size and electronic properties offer interesting bactericidal potential against Gram-positive and 723 
negative bacteria [166-168]. The direct disruption of the bacterial envelope by CNS appears to 724 
mainly occur at the cytoplasmic membrane [154]. The sharp edges of graphene insert/partially 725 
penetrate into the cytoplasmic membrane, leading to the extraction of large amounts of 726 
phospholipids (as shown for graphene nanosheets on E. coli) and consequent degradation of the 727 
membranes with release of intracellular RNA, electrolytes and proteins [155-157] (Figure 5). 728 
In addition, the oxidative nature of graphene may also induce lipid peroxidation [154, 169]. 729 
These antimicrobial effects of CNS seem to be generally favored by their small size. A decrease 730 
in the area of graphene nanosheets from 0.65 to 0.01 μm2 increased its bactericidal activity 731 
against E. coli up to 4-fold [154]; the decreased diameter of single-walled CNTs (0.9 - 1 nm) 732 
compared to multi-walled CNTs (15- 30 nm) allowed improved penetration into E. coli [157] 733 
and a much higher bactericidal effect against Gram-positive and Gram-negative bacteria [157, 734 
166].  735 
 736 
 737 
  
 738 
Figure 5.  Most relevant mechanisms for the direct penetration/disruption of the bacterial envelope 739 
by nanosized materials like cyclodextrins, siderophores, metal nanoparticles, carbon nanostructures, 740 
  
chitosan nanoparticles and dendrimers in Gram-negative (top) and -positive (bottom) bacteria. The 741 
double arrow vectors represent electrostatic interactions with the LPS, in Gram-negative bacteria 742 
(top), and the teichoic acids (wall teichoic acids and lipoteichoic acids) in Gram-positive bacteria 743 
(bottom). The envelope structures depicted are identified in Figure 1.  744 
 745 
4.5 ‘Membrane active’ peptides to disrupt and penetrate the bacterial envelope   746 
‘Membrane active’ peptides refer to antimicrobial peptides (AMPs) and cell-penetrating 747 
peptides (CPPs), both acting on the cytoplasmic membrane [170]. This ‘membrane activity’ 748 
allows AMPs and CPPs to respectively kill bacteria and transport drugs across the bacterial 749 
envelope. There is some confusion in the literature on the denominations; while AMPs are used 750 
to kill bacteria per se, CPPs are molecular transporters used to carry attached drugs into the 751 
cytosol of mammalian or bacterial cells (without cell lysis) [171, 172].  752 
AMPs naturally exist to protect higher organisms against pathogenic microorganisms [173]. 753 
AMPs selectively act against bacteria and not mammalian cells, because the higher fluidity and 754 
anionic character of bacterial CM, compared to that of mammalian cells CM, favour the 755 
peptide’s binding and insertion [26, 172, 174]. The higher fluidity of bacterial membranes 756 
derives from the absence of cholesterol and the presence of the fluid lipid PE. The higher 757 
anionic character, on the other hand, results from the presence of the anionic PG at the bacterial 758 
CM’s surface (in mammalian cells the anionic lipids are sequestered in the inner leaflet of the 759 
membrane and the outer leaflet is mostly decorated with zwitterionic phosphatidylcholine (PC) 760 
and sphingomyelin) [26, 55, 172, 174, 175]. Most AMPs are bactericidal by disrupting the 761 
bacterial CM [26], but some AMPs exist, such as buforin II, indolicin and pleurocidin, that 762 
cross the CM without disruption and lethally inhibit the synthesis/activity of DNA, RNA or 763 
proteins in the bacterial cytosol [172, 176]. 764 
  
CPPs, on the other hand, started to be earlier applied in mammalian cells and only more 765 
recently became also investigated to carry drugs into bacterial cells [171]. Hence, AMPs and 766 
CPPs have been mostly discussed separately, although similar mechanisms of ‘membrane 767 
activity’ have been proposed in the literature for CPPs and AMPs [171, 176]. Actually, despite 768 
the diversity of AMPs and CPPs (for a comprehensive description of different AMPs and CPPs 769 
the reader is referred to [176] and [177], respectively), most of them share general features: (i) 770 
small size, with less than 50 (AMPs) and 30 (CPPs) amino acids, (ii) net positive charge, and 771 
(iii) a significant amount of hydrophobic amino acids [175, 178, 179]. Therefore, we will 772 
discuss the interactions of AMPs and CPPs with the bacterial envelope together, as ‘membrane 773 
active’ peptides.  774 
 775 
4.5.1 Interactions of ‘membrane active’ peptides with the bacterial envelope 776 
As referred above, ‘membrane active’ peptides are active at the cytoplasmic membrane. 777 
Therefore, to reach the cytoplasmic membrane they first need to interact with the cell wall, 778 
through a rarely studied mechanism. Nevertheless, it is believed that the initial interaction is 779 
mediated by non-specific electrostatic interactions of the cationic peptides with the anionic LPS 780 
and teichoic acids, respectively in Gram-negative and -positive bacteria (Figure 6a) [172, 176]. 781 
Although a minority, anionic AMPs and CPPs also exist [176, 180]; we can thus envision that 782 
similarly to metal NPs, anionic AMPs and CPPs may be electrostatically attracted to the 783 
divalent cations bound to LPS/teichoic acids. Electrostatic interactions together with 784 
hydrophobic interactions may help the peptides to further translocate the OM in Gram-negative 785 
bacteria (Figure 6a) via a “self-promoted uptake” [90, 181-183]. Alternatively, it has been 786 
suggested that specific interactions at the cell wall surface, for instance with LPS, PE, or lipid 787 
II (peptidoglycan precursor), can promote the initial interaction of peptides with the bacterial 788 
envelope [26, 172, 174].  789 
  
Reaching the peptidoglycan, it has been assumed in the literature that the peptides (with a 790 
molecular weight typically below 5 kDa) may freely diffuse through the peptidoglycan mesh 791 
(considering the size exclusion for globular hydrophilic molecules of 50 kDa) [55, 182]. 792 
However, the role of peptidoglycan in the interaction with the peptides is not clear [55]. Still, 793 
the peptides should pass the cell wall very fast, as dissipation of the electrochemical gradient 794 
across the CMs is seen within a few seconds of bacteria exposure to AMPs [174, 184]. 795 
‘Membrane active’ peptides normally cross the cell wall without disrupting the OM in Gram-796 
negative bacteria [183]. An exception was recently found for the newly developed 7.7 nm large 797 
“star-shaped nanoengineered AMP polymer” (SNAPP), composed of cationic lysine and 798 
hydrophobic valine monomers polymerised from a polyamidoamine (PAMAM) dendritic core 799 
[183]. Due to its particular architecture, SNAPPs cannot transverse the OM via a “self-800 
promoted uptake” like general AMPs do [183]. Differently, after electrostatically binding to 801 
LPS, the SNAPPs (at high concentration) cause lethal OM’s destabilization and fragmentation 802 
[183]. SNAPPs can also further mildly perturb the CM and unbalance its ion movement [183]. 803 
This explains that the SNAPPs were not only active against Gram-negative bacteria, but also 804 
showed a moderate activity against Gram-positive bacteria [183].  805 
Reaching the cytoplasmic membrane, where typical AMPs and CPPs are active, the 806 
peptides first bind to the membrane by electrostatic interactions (Figure 6a) [26, 79, 176, 185]. 807 
When the peptides reach a threshold concentration on the membrane, which for AMPs is about 808 
full membrane coverage, the peptides insert themselves into the membrane bilayer via 809 
hydrophobic interactions (Figure 6a) [26, 79, 176, 185].  810 
The modes of membrane insertion/translocation depend on the peptide and the membrane 811 
[26]. For mammalian cells, CPPs have been proposed to translocate the mammalian membrane 812 
either by endocytosis or by direct penetration [170, 171]. Endocytosis is not applicable in 813 
bacteria. Differently, the direct penetration of CPPs in mammalian cells is proposed to occur 814 
  
via three possible models which are the same exact models proposed for the insertion of AMPs 815 
into bacterial CMs [171, 176]. Thus, carrier CPPs and antimicrobial AMPs should use the same 816 
mechanisms to force their translocation/insertion into the bacterial CM [186]. The three 817 
typically proposed models are: the barrel-stave pore, the toroidal pore and the carpet mechanism 818 
(Figure 6b) [171, 172, 174, 175]. In the barrel-stave pore the peptides insert perpendicularly 819 
to the membrane surface and pack together parallel to the hydrocarbon chains, forming an 820 
aqueous pore (Figure 6b) [172, 174, 175]. The cytoplasmic diameter of the barrel-stave pore 821 
formed by the AMP alamethicin has been estimated by structural studies to be around 1.8 nm 822 
[187]. In the toroidal pore model, the peptides also insert perpendicularly in the bilayer but 823 
they induce a toroid-like curvature in the membrane, so that lipid inner and outer leaflets are 824 
forced to bend towards one another stablishing a continuity [172, 174-176]. The pore is thus 825 
formed by both the inserted peptides and the phospholipid head groups (Figure 6b) [172, 174-826 
176]. The AMPs melittin and magainin form toroidal pores in lipid vesicles of 2.5-3 nm and 827 
3.0-5 nm, respectively [188, 189]. The (barrel-stave/toroidal) pores may allow the passage of 828 
molecules as big as 40 kDa, according to studies performed using the AMP maculatin that forms 829 
pores of 1.4 and 4.5 nm in diameter on lipid vesicles mimicking S. aureus membrane [190]. 830 
The formation of barrel-stave/toroidal pores requires that the peptide is long enough to span the 831 
hydrophobic core of the bilayer [190]. Differently, this is not needed in the carpet model, since 832 
the peptides absorb parallel to the bilayer surface and produce a detergent-like effect that 833 
eventually results in membrane disintegration into micelles (Figure 6b) [172, 174-176, 178]. 834 
Therefore, smaller peptides, can act via the carpet model [191]; this is the case for the AMPs 835 
aurein and cecropin, the later shown to form pores on E. coli of 4.2 nm in diameter [192].  836 
Instead of (or in addition to) self-assembling to form pores, adsorption of the peptides onto 837 
the membrane may dissipate the transmembrane potential, pH gradient and osmotic balance 838 
(Figure 6a) [178, 182, 190]. Different modes of action can be related, depending on the peptide 839 
  
concentration. For instance, at low concentrations the AMP cecropin was bactericidal to E. coli 840 
by dissipation of transmembrane electrochemical ion gradients (as judged from ion gradients 841 
dissipation in lipid vesicles), while higher concentrations were needed to release cytoplasmic 842 
contents [193]. The extent and duration of the membrane action of the peptides will dictate the 843 
viability of the cytoplasmic membrane. It may depend, besides peptide’s concentration, on the 844 
the peptide’s charge, hydrophobicity, sequence, structure and size [172, 176, 186, 194].   845 
Peptides able to remain inserted into the bacterial CM long enough to form irreversible pores 846 
or lesions will kill bacteria. This is the case for most AMPs. However, after insertion into the 847 
cytoplasmic membrane, CPPs (with its attached cargo) and the minority of AMPs that have 848 
their target in the bacterial cytosol (nucleic acids and proteins) still need to desorb from the CM 849 
to reach the cytosol. How exactly it happens is still a matter of debate. For the AMPs (with a 850 
cytosolic target) the peptides forming the pore might be randomly internalized by disintegration 851 
of the pore [186, 195]. The same mechanism may be reasoned to occur for CPPs. In addition, 852 
we can reason that peptides free in solution (which are expected to be in a relative higher 853 
number for CPPs than AMPs, owing to the specifically high affinity of AMPs to bacterial CMs) 854 
might flow into the bacterial cytosol via the formed pore. This may be possible if the formed 855 
pore is as large as 2-5 nm with a size exclusion of 40 kDa, as reported for AMPs [187-189, 856 
196]. 857 
 858 
4.5.2 CPPs as molecular transporters of antibacterial drugs 859 
CPPs have been explored to carry covalently conjugated antibiotics and, most commonly, 860 
antisense oligonucleotides across the bacterial envelope into the cytosol. 861 
The highly cationic 12 amino acids (a.a.) Pen peptide (RQIKIWFQNRRW, where R is 862 
arginine, Q is glutamine, I is isoleucine, K is lysine, W is tryptophan, F is phenylalanine and N 863 
is asparagine) was designed based on the 16 a.a penetratin (a well-known CPP for mammalian 864 
  
cells) and conjugated to the antibiotic tobramycin (lethal by ribosome inhibition), in order to 865 
increase the antibiotic’s uptake in persister E. coli and S. aureus [79]. Persister bacteria have 866 
decreased active transport and thus do not take up tobramycin. The Pen peptide alone caused 867 
extensive permeabilization which was per se bactericidal [79]. The conjugation of the antibiotic 868 
to the peptide, forming the conjugate Pentobra, decreased the permeabilization potential of the 869 
peptide [79]. Nevertheless, Pentobra killed more 4-6 logs of persister bacteria than the free 870 
tobramycin, showing the importance of the combined effect of tobramycin and the Pen peptide 871 
[79]. 872 
An earlier report prepared the cationic peptide (KFF)3K to permeabilize the Gram-negative 873 
OM to hydrophobic antibiotics (which penetrate intact OM very poorly, Figure 3) [197]. Pre-874 
treatment of bacteria with this peptide was found to sensitize enteric bacteria, such as E. coli, 875 
E. cloacae, K. pneumoniae, and S. typhimurium, to the hydrophobic antibiotic rifampin [197]. 876 
The peptide (KFF)3K was also found to permeabilize the OM of E. coli to antisense PNA [84, 877 
90, 93]. Since then, the peptide (KFF)3K has been widely covalently conjugated to antisense 878 
oligonucleotides to transport them into the bacterial cytosol. However, this has been nearly 879 
restricted to neutrally charged oligonucleotides (PNA and PMO) [90, 91, 198, 199], since the 880 
covalent conjugation to negatively charged is technically difficult [101]. Besides E. coli, 881 
(KFF)3K was also shown to improve the potency of PNAs and PMOs into the Gram-negative 882 
Salmonella Typhimurium, Klebsiella pneumoniae and Gram-positive Staphylococcus aureus, 883 
Bacillus subtilis and Corynebacterium efficiens [9, 200, 201]. This improved potency was 884 
ascribed to (KFF)3K mediated improved penetration [90]. Depending on the concentration, the 885 
(KFF)3K could also contribute to the killing efficacy of the antisense PNA by causing 886 
bactericidal cell leakage [90]. (KFF)3K could act not only against the cytoplasmic membrane, 887 
as expected, but it also disrupted the OM of E. coli [90, 183]. 888 
  
Other CPPs have been tested as well, which – compared to the peptide (KFF)3K – had a 889 
lower toxicity towards bacteria and when conjugated to an antisense PNA still allowed 890 
improved bactericidal effects. This was the case for the CPPs Tat (which is derived from the 891 
transactivator of transcription (TAT) of HIV and has the sequence GRKKRRQRRRPQ) [185, 892 
202, 203], (RXR)4XB and (RFR)4XB (G is glycine, P is proline and X is 6-aminohexanoic acid) 893 
[103, 199]. The Tat conjugates were tested against the Gram-positive Streptococcus pyogenes 894 
[185]. The (RXR)4XB and (RFR)4XB conjugates were tested against the Gram-positive Listeria 895 
monocytogenes in vitro and in a Caenorhabditis elegans infection model [103]. Conjugates of 896 
(RXR)4XB were also tested in vitro against the Gram-negative Salmonella Typhimurium, 897 
Klebsiella pneumoniae, Escherichia coli, and Shigella flexneri and also in vivo in a mice model 898 
infected with E. coli or S. flexneri [199]. 899 
Besides the peptide sequence, the extent of CPP permeabilization has been observed to 900 
depend on the bacteria. Vaara et al. showed that (KFF)3K was bactericidal per se against the 901 
Gram-positive Micrococcus tested, while it did not affect the viability of the tested Gram-902 
negative (E. coli, E. cloacae, K. pneumoniae, and S. typhimurium) [197]. Hatamoto et al. also 903 
found that the Gram-positive bacteria Bacillus subtilis and Corynebacterium efficiens exhibited 904 
increased susceptibility to (KFF)3K conjugated to antibacterial PNA than the Gram-negative E. 905 
coli; however, the Gram-negative bacterium Ralstonia eutropha was not affected by the 906 
conjugate [201]. Hence, it is not evident that a Gram-dependent susceptibility exists. 907 
The cargo transported by the peptide can also affect the conjugate’s translocation in different 908 
ways. For instance, in the aforementioned example of Pentobra, the conjugation of the cationic 909 
tobramycin to the Pen peptide decreased the permeabilization of E. coli and S. aureus compared 910 
to the Pen peptide alone [79]. In contrast, the conjugation of PNA to the (KFF)3K peptide made 911 
it more membrane-active towards E. coli than the (KFF)3K peptide alone [90]. The authors 912 
  
hypothesize that PNA, being neutrally charged, may increase the amphipathic character of the 913 
conjugate and thus benefit the conjugate’s interaction with the bacterial membranes [90].  914 
 915 
 916 
Figure 6. a) Interactions of ‘membrane active’ peptides with the bacterial cell envelope of 917 
Gram-negative and -positive bacteria, mainly determined by i) electrostatic interactions 918 
between the charged residues of the peptide and the LPS (in Gram-negative bacteria), the 919 
teichoic acids (in Gram-positive bacteria) and the phospholipids (in both Gram types), and ii) 920 
  
hydrophobic interactions between the hydrophobic residues of the peptide and the lipid layers 921 
[55, 183, 196]. b) Different models for the peptide insertion into the bacterial cytoplasmic 922 
membrane, similar for Gram-negative and -positive bacteria (thus the represented membrane 923 
phospholipids are not differentiated) [26, 175]. The envelope structures depicted are identified 924 
in Figure 1.  925 
 926 
4.6 Fusogenic liposomes to deliver drugs in bacteria 927 
Liposomes started to be extensively investigated already in the 1970’s for drug delivery into 928 
mammalian cells [204, 205], but only recently liposomes attracted interest to carry antibacterial 929 
drugs. Liposomes, together with poly(lactic-co-glycolic acid) (PLGA) NPs, are the most 930 
popular NPs used in antimicrobial studies. However, they are mainly used to improve the 931 
pharmacokinetics and the tolerability of antibiotics; in particular they are used to protect 932 
antibiotics from degradation in the body and/or to increase the local antibiotic concentration by 933 
sustained release [206-211]. Far less explored is the ability of some liposomes to overcome the 934 
bacterial envelope barrier by fusing with bacterial membranes, which may help to 935 
intracellularly deliver their antibacterial cargo [209]. Besides classic antibiotics, liposomes may 936 
offer an interesting solution for the delivery into bacteria of negatively charged 937 
oligonucleotides, as these can be easily complexed to cationic liposomes by electrostatic 938 
interactions. Fusion between liposomes and bacteria can only occur at the level of the Gram-939 
negative OM lipids and the Gram-positive cytoplasmic membrane, which will be discussed in 940 
the sections below. 941 
 942 
4.6.1 Interactions of liposomes with the envelope of Gram-negative bacteria 943 
For liposomes to be able to reach the OM lipids for fusion, they first need to overcome the 944 
LPS. Cationic liposomes will bind electrostatically to the negatively charged bacteria surface 945 
  
[212]; in particular, binding to the Gram-negative LPS may lead to LPS chains (O-antigen and 946 
core) flattening so that liposomes make contact with the negatively charged lipids of the OM 947 
[213] (top panel of Figure 7). For negatively charged liposomes, such as 948 
dipalmitoylphosphatidylcholine (DPPC) /dimiristoylphosphatidylglycerol (DMPG) liposomes 949 
(Figure 8), Ca2+ is typically added to the liposome suspension which can limit the electrostatic 950 
repulsion between the anionic liposomes and the LPS; in addition, Ca2+ may bridge the 951 
liposomes-OM interaction and contribute to dehydrate the OM’s PE thereby improving fusion 952 
[213]. Apart from Ca2+, other divalent cations can also mediate fusion; nevertheless, cations 953 
with larger ionic radius seemed to be less efficient, as they probably increase the liposome-OM 954 
distance [213]. Electrostatic attraction of anionic liposomes to the metal cations bound to the 955 
LPS may also contribute to the initial interaction with the cell wall [135, 137]. 956 
When in contact with the bacterial OM lipids, liposomes may then fuse with them. Fusion 957 
occurs when two bilayers, in this case the liposome bilayer and the OM lipid bilayer, merge 958 
into a single bilayer [214]. Fusion with the OM lipids is fast and occurs spontaneously by 959 
hydrophobic and van der Waals interactions [11]. Fusion critically depends on the lipid 960 
composition of the two bilayers involved [214]. The PE moiety is the most commonly referred 961 
fusogenic lipid [215, 216]. PE has a low hydration of its polar head group, which may decrease 962 
the fluid spacing between bilayers and thereby facilitates energetically favorable interactions 963 
between lipid bilayers [215-217]. In addition, PE has a cone-shaped molecular shape (small 964 
head cross section and large chain cross section) and ability to promote bilayer-to-hexagonal 965 
phase transition which may trigger membrane destabilization [215, 216]. Therefore, PE, in the 966 
form of the dioleoylphosphatidylethanolamine (DOPE) lipid (Figure 8), has been incorporated 967 
into liposomes to produce fusogenic liposomes. DOPE containing liposomes have successfully 968 
improved antibiotics penetration into the Gram-negative P. aeruginosa, E. coli, Klebsiella spp. 969 
and A. Baumannii [209, 217, 218] and have intracellularly delivered NAMs into the Gram-970 
  
negative H. pylori [219]. In particular, the improved penetration of antibiotics in P. aeruginosa 971 
allowed a decrease of the minimum inhibitory concentration (MIC) of tobramycin of at least 972 
640-fold [218], and of meropenem (a carbapenem) up to 4-fold [209]. Also, the delivery of 973 
vancomycin (too large to cross the bacterial envelope of Gram-negative bacteria (Figure 3b) 974 
reduced the MIC of vancomycin by up to 85-fold in E. coli and A. Baumannii, up to 20-fold in 975 
Klebsiella spp. and up to 10-fold in P. aeruginosa [217]. 976 
Liposomes without DOPE have been also reported to be able to intimately interact and even 977 
fuse with bacteria, improving the permeation of antibiotics. A popular formulation is 978 
DPPC/DMPG negatively charged liposomes, frequently called “fluidosomes” [213, 218, 220-979 
222]. This designation comes from the ability of DMPG to increase the fluidity of liposomes; 980 
indeed, DMPG is a phospholipid with short acyl chains and a high number of unsaturated bonds 981 
which results in a relatively low gel-liquid crystalline transition temperature (Tc) [223, 224]. 982 
Studies report efficient interaction of DPPC/DMPG liposomes with bacteria, improving the 983 
permeation of antibiotics [220-222] and even of one antisense PS DNA oligonucleotide [225]. 984 
However, it has also been reported that encapsulation of antibiotics in DPPC/DMPG liposomes 985 
even lowered the antimicrobial efficiency when compared to free antibiotic [209]. It was latter 986 
clarified that DPPC/DMPG are not fusogenic per se and that their improved antibiotic 987 
permeation depends on the presence of divalent cations as Ca2+ to reduce the electrostatic 988 
repulsion between the negatively charged liposomes and the bacteria surface [213, 218].   989 
In addition, intimate interactions were observed between the more rigid liposomal 990 
formulations, such as distearoylglycerophosphocholine (DSPC)/cholesterol (Chol), 991 
phosphatidylcholine (PC)/Chol/dioleoyltrimethylammoniumpropane (DOTAP) or DPPC/Chol 992 
(Figure 8), and Gram-negative bacteria like P. aeruginosa and Burkholderia cenocepacia [212, 993 
226, 227]. Despite the inclusion of lipids with increased Tc and Chol (which should increase 994 
liposomes rigidity/stability), fusion/adhesion of these liposomes with the bacterial OM was 995 
  
reported [212, 226, 227]. However, others have seen that the inclusion of only 10% Chol 996 
dramatically lowered  DPPC/DMPG fusion in P.aeruginosa [213, 218]. 997 
The studies using DPPC/DMPG and more rigid liposomes (containing Chol and DSPC) 998 
show that fusion with bacterial membranes may occur to some extent using non-DOPE 999 
liposomes. Although there is no PE in the liposomes, there is a high amount of PE in the Gram-1000 
negative OM that may mediate fusion [55, 228]. Indeed DPPC/DMPG liposomes cannot fuse 1001 
with the more rigid cytoplasmic membrane of human cells (which contain cholesterol and have 1002 
PC as the major lipid on their membrane surface and a minor amount of PE sheltered in the 1003 
inner CM’s leaflet) [55, 228]. However, DPPC/DMPG liposomes could fuse with Gram-1004 
negative bacteria and the higher the PE content of the bacterial OM, the better fusion occured 1005 
[213, 228]. When PE (in the form of DOPE) is also included in liposomes, composed for 1006 
instance of  DPPC/DMPG liposomes [218], DPPC/Chol hemisuccinate liposomes [217] or 1007 
PC/Octadecylamine [209], the tendency for fusion between bacteria and liposomes is further 1008 
enhanced, as seen by the significant improvement of the antibiotics efficacy [212, 217, 218].  1009 
Although the composition of the liposomes affects their fusion ability, a clear effect of the 1010 
size of liposomes has not been observed [218, 225]. From the bacteria side, beside the PE 1011 
content, the effect of other bacterial features on fusion is not well understood and may depend 1012 
on fine details. For instance, various P. aeruginosa strains showed different degrees of fusion 1013 
with PC/Chol/DOTAP liposomes, while the expression of one 18-kDa OMP was found to be 1014 
positively correlated with fusion [212].  1015 
Upon fusion with the Gram-negative OM lipids the incorporated antibiotics/antibacterial 1016 
oligonucleotides will be delivered into the periplasm (top panel of Figure 7). From here, the 1017 
molecules will have to cross the viscous periplasmic space and will make contact with the 1018 
peptidoglycan, where antibiotics that disrupt the peptidoglycan synthesis have their site of 1019 
action. Other antibiotics and oligonucleotides acting rather on the cytosol will have to cross the 1020 
  
peptidoglycan and the cytoplasmic membrane as well, as discussed in sections 3.1 and 3.2, 1021 
respectively [36]. 1022 
 1023 
4.6.2 Interactions of liposomes with the envelope of Gram-positive bacteria 1024 
Liposomes for the delivery of antibiotics and oligonucleotides into Gram-positive bacteria 1025 
will first contact with the teichoic acids. It can be reasoned that liposomes will electrostatically  1026 
interact with teichoic acids the same way that liposomes interact with LPS (described in the 1027 
previous section), so that liposomes binding to and flattening of the teichoic acids layer may 1028 
occur  (bottom panel of Figure 7). However, for fusion to occur in Gram-positive bacteria, 1029 
liposomes do not only have to overcome the teichoic acids but also the thick peptidoglycan, in 1030 
order to contact and fuse with the cytoplasmic membrane lipids.  1031 
It is currently unknown whether or not liposomes could overcome the peptidoglycan of 1032 
Gram-positive bacteria (bottom panel of Figure 7). The studies on fusion of liposomes with 1033 
Gram-positive bacteria are few; they were performed with the bacteria S. aureus, Enterococcus 1034 
faecalis and Streptococcus agalactiae and liposomes composed of DPPC/DMPG (in the 1035 
presence of Ca2+), egg PC/DMPG/DSPE-PEG, DPPC/DOTAP/DSPE-PEG (with and without 1036 
wheat germ agglutinin as a targeting moiety), dimyristoylphosphocholine (DMPC)/Chol/DHP 1037 
(dihexadecylhydrogenphosphate) and DMPC/Chol/ DPPS (dipalmitoylphosphatidylserine), 1038 
(Figure 8) [213, 229-231]. These studies suggest fusion to explain the improved efficiency of 1039 
the encapsulated compared to the free antimicrobial drug [213, 229-231]. Also, one study in S. 1040 
aureus, resistant to β-lactam antibiotics, showed that the bacteria susceptibility could be 1041 
improved by the use of anionic egg PC/DMPG/DSPE-PEG liposomes, carrying a PS DNA to 1042 
downregulate a gene of resistance to β-lactams [229]. The PS DNA was first complexed with 1043 
the cationic polymer polyethyleneimine (PEI), resulting in an 80 nm complex that was 1044 
subsequently encapsulated into the liposomes [229]. The observed downregulation was 1045 
  
interpreted as a result of liposomal fusion and intracellular delivery of the PS DNA [229], but 1046 
the authors did not report the effect of the complex alone nor the interaction of liposomes with 1047 
S. aureus. Actually only one of the studies on Gram-positive bacteria explicitly demonstrates 1048 
interaction between liposomes and bacteria, using flow cytometry and fluorescence microscopy 1049 
[232], and none of them show experimental evidence of direct intracellular delivery by 1050 
liposomes. Therefore, it may be possible that liposomes only enable sustained local drug release 1051 
close to the Gram-positive bacterial surface [230], resulting in an increased drug concentration 1052 
gradient across the bacterial envelope. For drugs with limited (but not impossible) permeation 1053 
of the bacterial envelope this may be sufficient to improve the drug diffusion across the 1054 
peptidoglycan and cytoplasmic membrane [230]. Note that local drug release may also 1055 
contribute to the delivery into Gram-negative bacteria, especially when non-fusogenic 1056 
liposomes (liposomes without DOPE) are employed.  1057 
Even when interaction of liposomes and the OM of Gram-negative bacteria occurs, it 1058 
remains very challenging to experimentally distinguish between adhesion of the liposomes on 1059 
the OM with (only) local drug release and fusion of the liposomes with the OM followed by 1060 
intracellular delivery. This is due to technological limitations. Electron microscopy typically 1061 
shows generic interaction/adhesion at the bacterial envelope. Immunohistochemistry combined 1062 
with TEM can be useful to find intracellularly delivered drugs, but it depends on the availability 1063 
of specific antibodies. Epi-fluorescence microscopy and flow cytometry based on fluorescent 1064 
constructs (liposomes carrying fluorescent molecules) can hardly distinguish between surface 1065 
adhered fluorescent constructs and internalized fluorescent molecules, since the optical 1066 
resolution limit is rather close to the bacteria size (optical resolution being typically not higher 1067 
than ~0.25 µm while width of most bacteria ~0.5-1 µm). Fillion et al. proposed to distinguish 1068 
in E. coli surface adhesion of DPPC/DPMG liposomes (carrying a fluorescently labelled PS 1069 
DNA) from intracellular delivery of the fluorescently labelled PS DNA by incubating E. coli 1070 
  
with the constructs respectively at 4 °C vs 37 °C and measuring the fluorescence by 1071 
fluorescence-activated cell sorting (FACS) [225]. However, it is our belief that incubation at 4 1072 
°C is not a sufficiently good control, because adhesion at 4 °C may be lower than the adhesion 1073 
that can occur at 37 °C. Differently, our group showed recently the use of fluorescence 1074 
microscopy to visualize bacteria with fluorescence coming exclusively from intracellularly 1075 
delivered fluorescent molecules; fluorescence coming from constructs remaining adhered on 1076 
the OM could be removed by a mild triton wash [219]. Thus, the fraction of molecules actually 1077 
delivered intracellularly by the liposomes could the quantified based on the fluorescence 1078 
intensity [219].  1079 
 1080 
  
 1081 
Figure 7. Illustration of the intracellular delivery mechanism by liposomes able to fuse with bacterial 1082 
membranes. In Gram-negative bacteria (top), liposomes fuse with the outer membrane (adapted 1083 
from [213]). At the Gram-positive envelope (bottom), liposomes would have to cross the thick 1084 
peptidoglycan layer to fuse with the cytoplasmic membrane, via an undetermined mechanism. The 1085 
envelope structures depicted are identified in Figure 1.  1086 
 1087 
 1088 
  
 1089 
Figure 8. Representative struture of common lipids used in liposomal formulations applied to 1090 
bacteria. DOPE: dioleoylphosphatidylethanolamine; DMPG: dimiristoylphosphatidylglycerol; 1091 
DPPC: dipalmitoylphosphatidylcholine; DSPC: distearoylglycerophosphocholine; DOTAP: 1092 
dioleoyltrimethylammoniumpropane; DMPC: dimyristoylphosphocholine; DHP: 1093 
dihexadecylhydrogenphosphate; DPPS: dipalmitoylphosphatidylserine; Chol: cholesterol. 1094 
 1095 
 1096 
5. Conclusions and future perspectives  1097 
Nanoparticles and molecular transporters may provide valuable tools to overcome the 1098 
bacterial cell envelope which limits the internalization of bactericidal drugs. As discussed along 1099 
this review, such NPs/molecules can be (i) bactericidal per se, if they directly penetrate the 1100 
bacterial envelope causing envelope disruption (metal NPs, CNS, chitosan NPs, dendrimers and 1101 
AMPs), (ii) carriers of bactericidal drugs that penetrate the bacterial envelope with the attached 1102 
drugs without necessarily causing disruption (CPPs, siderophores and eventually 1103 
cyclodextrins), or  (iii) delivery vectors that do not penetrate bacteria but intracellularly deliver 1104 
  
the drugs into bacteria (fusogenic liposomes). According to the current knowledge CPPs and 1105 
liposomes are the best positioned candidates. These are especially interesting to intracellularly 1106 
transport novel NAM drugs which suffer from very poor internalization, in particular CPPs to 1107 
transport neutral NAMs and liposomes to transport anionic NAMs. NAMs are promising to be 1108 
used as antibacterial drugs, by targeting essential bacterial genes, and as drug adjuvants, to 1109 
restore bacteria susceptibility to antibiotics. NAMs can provide a virtual endless source of 1110 
drugs, since even if the bacterial target undergoes a mutation the NAM can be easily redesigned 1111 
to become effective again. Therefore, combining NAMs with a CPP/liposomal carrier holds 1112 
promise to address the antibiotic crisis and redirect the fight against bacterial infections. 1113 
Nevertheless, the design of efficient constructs would benefit from a better understanding of 1114 
the dynamics at the bacterial envelope interface. X-ray crystallography has allowed very useful 1115 
characterization of some protein channels and more still need to be studied. Still, it would be 1116 
interesting that these studies could be complemented with investigating the real-time transport 1117 
in living bacterial cells, so that the eventual adaptability of bacterial envelope’s permeability 1118 
could be evaluated and the chances of the NPs to overcome the bacterial envelopes could be 1119 
fully understood. The possibility to test transport in live bacteria is challenged by the small size 1120 
of bacterial cells which limits the direct appreciation of NPs internalization by common 1121 
techniques as flow cytometry and fluorescence microscopy. Super-resolution microscopy is 1122 
starting to be used to elucidate the dynamics of some bacterial physiological processes [233-1123 
235]. We envision that its continuous advance and availability will position super-resolution 1124 
microscopy as a critical tool, in the future, to evaluate NPs interaction with bacterial cells and 1125 
boost the application of nanomedicine towards bacterial cells. 1126 
 1127 
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